MSB

3.16%

98.0¢ mesoblast limited

MSB to dispute FDA finding in Type A meeting, page-30

First 30 Last

Share
Profile

Follow
tubbyguts

3,346 Posts.

269

02/10/20

13:01

Post #: 47808286
Share

Originally posted by Tiggietrain1719: ↑

My confusion about this meeting is that all of the evidence that MSB have, has already been presented, voted on with an overwhelming majority by ODAC and still knocked back. What more can they present or do to overturn it?

Expand

Another trial and refined potency metrics

Originally posted by MelbourneBoy: ↑

If you look at this situation from both a scientific & commercial perspective, a fundamental question of the FDA is this:

Can you prove that every patient gets a uniform dose and that the dose is equally effective?

Now from one side you could say that if 70% of patients live when only 15% did previously, does it matter? More people (kids in this case) when there is no real alternative.

However, consider this:

What if the 30% who died did so because the dose was not as effective as it was meant to be?
Some patients would then have had a reduced chance of survival and them, their families or their insurers have paid for a treatment that was less effective than it otherwise may have been.

This is a pretty big question and central to the work Mesoblast now needs to do.

They either need to show the FDA how their methods of uniformity and dose are appropriate, or find a way to modify their methods to better reflect FDA custom and practise.

Note: I am a holder, I am very supportive of the company, but I am also a TGA license holder here in Australia, so do have some insight into how these regulators work.

Good luck to everyone. Lets hope updates aren't too far away.

Expand

bingo. Pay attention to this guy

MSB Price at posting: $3.37 Sentiment: Hold Disclosure: Held
6 Upvote

0 Great analysis

Reply

Top Stories

Emerald & Azure score Digger & Dealer awards

KCC

Kincora partners with Woomera to advance Mongolian copper-gold play

BAS

Bass Oil officially cites mid-October as final date for Kiwi-1 production test – a well first drilled 21 years ago

SGA

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Bitcoin: Current State of Play & Where to Next | Swyftx

There are more pages in this discussion • 988 more messages in this thread...

First 30 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last 98.0¢		Change 0.030(3.16%)		Mkt cap ! $1.098B

Open	High	Low	Value	Volume
94.5¢	98.0¢	93.5¢	$2.373M	2.466M

Buyers (Bids)

No.	Vol.	Price($)
16	93312	97.5¢

Sellers (Offers)

Price($)	Vol.	No.
98.0¢	273746	13

View Market Depth

No.	Vol.	Price($)
27	103243	0.970
17	119814	0.965
16	185275	0.960
12	182999	0.955
13	176363	0.950

Price($)	Vol.	No.
0.975	102138	11
0.980	296806	18
0.985	242011	12
0.990	154986	14
0.995	116629	5

Last trade - 14.20pm 12/08/2024 (20 minute delay)

MSB (ASX) Chart

MSB to dispute FDA finding in Type A meeting, page-30

Emerald & Azure score Digger & Dealer awards

Kincora partners with Woomera to advance Mongolian copper-gold play

Bass Oil officially cites mid-October as final date for Kiwi-1 production test – a well first drilled 21 years ago

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Bitcoin: Current State of Play & Where to Next | Swyftx

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

MSB to dispute FDA finding in Type A meeting, page-30

Top Stories

Emerald & Azure score Digger & Dealer awards

Kincora partners with Woomera to advance Mongolian copper-gold play

Bass Oil officially cites mid-October as final date for Kiwi-1 production test – a well first drilled 21 years ago

Sarytogan promises good returns on Kazakhstan project, but the market is uncertain

Bitcoin: Current State of Play & Where to Next | Swyftx

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News